Medexus Pharmaceuticals Inc.
MDP.TOTSXHealthcare● Active
$3.95
+$0.04(+1.02%)
Market Cap$127586501
P/E Ratio—
52W High$4.17
52W Low$2.47
Medexus Pharmaceuticals Inc. (MDP.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MDP.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 11, 2026EPS Actual
$0.00
Est. -$0.03 · +110.7%
Revenue
$0.03B
Est. $0.03B · -0.1%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 11, 2026
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
MDP.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 30, 2026 | -$0.02 | — | — | — | $0.04B | — |
| ◌ Q2 FY2026 | Jun 30, 2026 | -$0.01 | — | — | — | $0.04B | — |
| ▲ Q1 FY2026 | Feb 11, 2026 | -$0.03 | $0.00 | +110.7% | $0.03B | $0.03B | -0.1% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.03 | -$0.01 | +52.5% | $0.03B | $0.04B | -2.7% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.04 | $0.03 | +167.9% | $0.03B | $0.03B | -3.9% |
| ▲ Q2 FY2025 | Jun 26, 2025 | -$0.09 | -$0.03 | +68.1% | $0.04B | $0.04B | -1.4% |
| ▲ Q1 FY2025 | Feb 5, 2025 | -$0.13 | $0.03 | +123.1% | $0.03B | $0.04B | -16.8% |
| — Q4 FY2024 | Nov 7, 2024 | — | $0.00 | — | $0.03B | $0.04B | -34.5% |
Q2 FY2026
Jun 30, 2026
EPS Actual
—
EPS Est.
-$0.02
EPS Surpr.
—
Revenue
—
Q2 FY2026
Jun 30, 2026
EPS Actual
—
EPS Est.
-$0.01
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 11, 2026Beat
EPS Actual
$0.00
EPS Est.
-$0.03
EPS Surpr.
+110.7%
Revenue
$0.03B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.01
EPS Est.
-$0.03
EPS Surpr.
+52.5%
Revenue
$0.03B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.04
EPS Surpr.
+167.9%
Revenue
$0.03B
Q2 FY2025
Jun 26, 2025Beat
EPS Actual
-$0.03
EPS Est.
-$0.09
EPS Surpr.
+68.1%
Revenue
$0.04B
Q1 FY2025
Feb 5, 2025Beat
EPS Actual
$0.03
EPS Est.
-$0.13
EPS Surpr.
+123.1%
Revenue
$0.03B
Q4 FY2024
Nov 7, 2024
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.17 | $0.19 | $0.20 | 1 |
| Q4 FY2027 | $0.15 | $0.16 | $0.17 | 1 |
| Q3 FY2027 | $0.12 | $0.13 | $0.14 | 1 |
| Q2 FY2027 | $0.06 | $0.07 | $0.07 | 1 |
| Q1 FY2027 | $0.13 | $0.14 | $0.15 | 1 |
| Q4 FY2026 | $0.12 | $0.13 | $0.13 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Feb 11, 2026 | +110.7% | $2.84 | $2.81 | -1.06% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +52.5% | $2.68 | $2.70 | +0.75% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +167.9% | $2.64 | $2.75 | +4.17% |
| ▲ Q2 FY2025 | Jun 26, 2025 | +68.1% | $3.35 | $3.15 | -5.97% |
| ▲ Q1 FY2025 | Feb 5, 2025 | +123.1% | $3.87 | $3.79 | -2.07% |
| — Q4 FY2024 | Nov 7, 2024 | — | $2.22 | $2.20 | -0.90% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +100.0% | $2.23 | $2.27 | +1.79% |
| ▲ Q2 FY2024 | Jun 25, 2024 | +250.0% | $1.68 | $1.69 | +0.60% |
Q1 FY2026-1.06%
Report Date
Feb 11, 2026
EPS Beat/Miss
+110.7%
Price Before
$2.84
Price After
$2.81
Q4 FY2025+0.75%
Report Date
Nov 12, 2025
EPS Beat/Miss
+52.5%
Price Before
$2.68
Price After
$2.70
Q3 FY2025+4.17%
Report Date
Aug 12, 2025
EPS Beat/Miss
+167.9%
Price Before
$2.64
Price After
$2.75
Q2 FY2025-5.97%
Report Date
Jun 26, 2025
EPS Beat/Miss
+68.1%
Price Before
$3.35
Price After
$3.15
Q1 FY2025-2.07%
Report Date
Feb 5, 2025
EPS Beat/Miss
+123.1%
Price Before
$3.87
Price After
$3.79
Q4 FY2024-0.90%
Report Date
Nov 7, 2024
EPS Beat/Miss
—
Price Before
$2.22
Price After
$2.20
Q3 FY2024+1.79%
Report Date
Aug 7, 2024
EPS Beat/Miss
+100.0%
Price Before
$2.23
Price After
$2.27
Q2 FY2024+0.60%
Report Date
Jun 25, 2024
EPS Beat/Miss
+250.0%
Price Before
$1.68
Price After
$1.69
Avg Beat Reaction-0.26%
Beat Rate7 / 8 quarters
Largest Move-5.97% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MDP.TO ends December
Medexus Pharmaceuticals Inc. (MDP.TO) most recently reported earnings on February 11, 2026 for Q1 FY2026, posting EPS of $0.00 — beating the analyst consensus of $-0.03 by +110.7%. MDP.TO has beaten EPS estimates for 7 consecutive quarters. The next MDP.TO earnings date is expected around September 1, 2026.
Each quarter, investors track MDP.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MDP.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MDP.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MDP.TO earnings · 5 questionsMedexus Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. MDP.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MDP.TO historically reports after market close (AMC).
MDP.TO earnings datewhen is MDP.TO earningsMDP.TO next earnings datewhen does MDP.TO report earningsMDP.TO earnings calendar
▸ Source: FMP · Medexus Pharmaceuticals Inc. SEC filings · US GAAP · Medexus Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026